{"id":7558,"date":"2025-09-09T14:41:16","date_gmt":"2025-09-09T12:41:16","guid":{"rendered":"https:\/\/fth.es\/?p=7558"},"modified":"2025-09-24T10:09:48","modified_gmt":"2025-09-24T08:09:48","slug":"pearl","status":"publish","type":"post","link":"https:\/\/fth.es\/en\/pearl\/","title":{"rendered":"Estudio cl\u00ednico PEARL (PotEntial of Asciminib in the eaRly treatment of CML)"},"content":{"rendered":"<div>\n<p>\u00a0<\/p>\n<\/p>\n<\/div>\n<h1>\n<p class=\"el-title uk-margin-top uk-margin-remove-bottom\">PEARL<\/p>\n<\/p>\n<\/h1>\n<h4>\n<p class=\"el-title uk-margin-top uk-margin-remove-bottom\">(PotEntial of Asciminib in the eaRly treatment of CML)<\/p>\n<\/h4>\n<h4>\n<p class=\"el-title uk-margin-top uk-margin-remove-bottom\">La Fundaci\u00f3n Te\u00f3filo Hernando (FTH) participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica (LMC) en fase cr\u00f3nica reci\u00e9n diagnosticados<\/p>\n<\/h4>\n<div>\n<p>\u00a0<\/p>\n<\/p>\n<\/div>\n<h1>Potencial del asciminib en el tratamiento de la LMC<\/h1>\n<div>\n<h4><strong>El objetivo del estudio es investigar la seguridad y eficacia de asciminib como monoterapia y en combinaci\u00f3n con nilotinib en la consecuci\u00f3n y mantenimiento de respuestas moleculares profundas estables; reducir la progresi\u00f3n de la enfermedad e incrementar las oportunidades de alcanzar una remisi\u00f3n libre de tratamiento (TFR).<\/strong><\/h4>\n<p>Tambi\u00e9n se pretende determinar si este tratamiento en investigaci\u00f3n puede ser m\u00e1s eficaz que las terapias actualmente utilizadas, reduciendo al mismo tiempo la frecuencia y gravedad de los efectos adversos, lo que repercutir\u00eda en una mejora de la calidad de vida de los pacientes.<\/p>\n<p>Este proyecto de investigaci\u00f3n cuenta con el apoyo de Novartis Pharma AG y est\u00e1 desarrollado por el Grupo Espa\u00f1ol de Leucemia Mieloide Cr\u00f3nica (GELMC) y la Fundaci\u00f3n GIMEMA (Grupo Italiano de Hematolog\u00eda), co-promotores del estudio, que se est\u00e1 llevando a cabo en varios hospitales de Espa\u00f1a e Italia.<\/p>\n<p>La FTH es responsable de la puesta en marcha y apertura de centros, monitorizaci\u00f3n y gesti\u00f3n del estudio en los diferentes hospitales de Espa\u00f1a durante los 7 a\u00f1os de duraci\u00f3n del ensayo (2 a\u00f1os de reclutamiento, 2 a\u00f1os de fase central de tratamiento, 2 a\u00f1os de fase de consolidaci\u00f3n del tratamiento y 1 a\u00f1o libre de tratamiento).<\/p>\n<p>El estudio est\u00e1 autorizado por la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) desde el 24 de junio de 2025 y, hasta la fecha, 14 de los 15 centros participantes en Espa\u00f1a han comenzado el reclutamiento en junio de 2025, habi\u00e9ndose incluido ya 12 pacientes de un total estimado de 80 en los centros espa\u00f1oles.<\/p>\n<p><strong>Para m\u00e1s informaci\u00f3n:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06409936\">Ficha del estudio en ClinicalTrials.gov<\/a><\/li>\n<li><a href=\"https:\/\/fth.es\/servicios-de-investigacion\/investigacion-clinica\/\">Investigaci\u00f3n cl\u00ednica en la Fundaci\u00f3n Te\u00f3filo Hernando<\/a><\/li>\n<\/ul>\n<\/div>\n<p><!--more--><br \/>\n<!-- {\"type\":\"layout\",\"children\":[{\"type\":\"section\",\"props\":{\"image\":\"wp-content\\\/uploads\\\/2025\\\/09\\\/examen-medico-1.jpg\",\"image_effect\":\"parallax\",\"image_parallax_bgy\":\"240 82%\",\"image_position\":\"center-center\",\"image_size\":\"cover\",\"media_overlay\":\"rgba(2, 2, 2, 0.65)\",\"padding\":\"none\",\"padding_remove_horizontal\":true,\"padding_remove_top\":true,\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"middle\",\"width\":\"\"},\"children\":[{\"type\":\"row\",\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\"},\"children\":[{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<p>\\u00a0<\\\/p>\\n\n\n<p><\\\/p>\",\"margin\":\"default\"}},{\"type\":\"headline\",\"props\":{\"content\":\"\n\n<p class=\\\"el-title uk-margin-top uk-margin-remove-bottom\\\">PEARL<\\\/p>\\n\n\n<p><\\\/p>\",\"text_align\":\"center\",\"title_color\":\"muted\",\"title_element\":\"h1\",\"title_style\":\"h1\"}},{\"type\":\"headline\",\"props\":{\"block_align\":\"center\",\"content\":\"\n\n<p class=\\\"el-title uk-margin-top uk-margin-remove-bottom\\\">(PotEntial of Asciminib in the eaRly treatment of CML)<\\\/p>\",\"maxwidth\":\"2xlarge\",\"text_align\":\"center\",\"title_color\":\"muted\",\"title_element\":\"h4\",\"title_style\":\"h4\"}},{\"type\":\"headline\",\"props\":{\"block_align\":\"center\",\"content\":\"\n\n<p class=\\\"el-title uk-margin-top uk-margin-remove-bottom\\\">La Fundaci\\u00f3n Te\\u00f3filo Hernando (FTH) participa en un ensayo cl\\u00ednico multic\\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\\u00f3nica (LMC) en fase cr\\u00f3nica reci\\u00e9n diagnosticados<\\\/p>\",\"maxwidth\":\"2xlarge\",\"text_align\":\"center\",\"title_color\":\"muted\",\"title_element\":\"h4\",\"title_style\":\"h4\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<p>\\u00a0<\\\/p>\\n\n\n<p><\\\/p>\",\"margin\":\"default\"}}]}],\"props\":{\"margin\":\"remove-vertical\",\"width\":\"small\"}}],\"name\":\"ENCABEZADO\"},{\"type\":\"section\",\"props\":{\"image_position\":\"center-center\",\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"middle\",\"width\":\"default\"},\"children\":[{\"type\":\"row\",\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\"},\"children\":[{\"type\":\"headline\",\"props\":{\"content\":\"Potencial del asciminib en el tratamiento de la LMC\",\"title_element\":\"h1\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<h4><strong>El objetivo del estudio es investigar la seguridad y eficacia de asciminib como monoterapia y en combinaci\\u00f3n con nilotinib en la consecuci\\u00f3n y mantenimiento de respuestas moleculares profundas estables; reducir la progresi\\u00f3n de la enfermedad e incrementar las oportunidades de alcanzar una remisi\\u00f3n libre de tratamiento (TFR).<\\\/strong><\\\/h4>\\n\n\n<p>Tambi\\u00e9n se pretende determinar si este tratamiento en investigaci\\u00f3n puede ser m\\u00e1s eficaz que las terapias actualmente utilizadas, reduciendo al mismo tiempo la frecuencia y gravedad de los efectos adversos, lo que repercutir\\u00eda en una mejora de la calidad de vida de los pacientes.<\\\/p>\\n\n\n<p>Este proyecto de investigaci\\u00f3n cuenta con el apoyo de Novartis Pharma AG y est\\u00e1 desarrollado por el Grupo Espa\\u00f1ol de Leucemia Mieloide Cr\\u00f3nica (GELMC) y la Fundaci\\u00f3n GIMEMA (Grupo Italiano de Hematolog\\u00eda), co-promotores del estudio, que se est\\u00e1 llevando a cabo en varios hospitales de Espa\\u00f1a e Italia.<\\\/p>\\n\n\n<p>La FTH es responsable de la puesta en marcha y apertura de centros, monitorizaci\\u00f3n y gesti\\u00f3n del estudio en los diferentes hospitales de Espa\\u00f1a durante los 7 a\\u00f1os de duraci\\u00f3n del ensayo (2 a\\u00f1os de reclutamiento, 2 a\\u00f1os de fase central de tratamiento, 2 a\\u00f1os de fase de consolidaci\\u00f3n del tratamiento y 1 a\\u00f1o libre de tratamiento).<\\\/p>\\n\n\n<p>El estudio est\\u00e1 autorizado por la Agencia Espa\\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) desde el 24 de junio de 2025 y, hasta la fecha, 14 de los 15 centros participantes en Espa\\u00f1a han comenzado el reclutamiento en junio de 2025, habi\\u00e9ndose incluido ya 12 pacientes de un total estimado de 80 en los centros espa\\u00f1oles.<\\\/p>\\n\n\n<p><strong>Para m\\u00e1s informaci\\u00f3n:<\\\/strong><\\\/p>\\n\n\n<ul>\\n\n\n<li><a href=\\\"https:\\\/\\\/clinicaltrials.gov\\\/study\\\/NCT06409936\\\">Ficha del estudio en ClinicalTrials.gov<\\\/a><\\\/li>\\n\n\n<li><a href=\\\"https:\\\/\\\/fth.es\\\/servicios-de-investigacion\\\/investigacion-clinica\\\/\\\">Investigaci\\u00f3n cl\\u00ednica en la Fundaci\\u00f3n Te\\u00f3filo Hernando<\\\/a><\\\/li>\\n<\\\/ul>\",\"margin\":\"default\"}}]}]}]}],\"version\":\"4.5.24\"} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 PEARL (PotEntial of Asciminib in the eaRly treatment of CML) La Fundaci\u00f3n Te\u00f3filo Hernando (FTH) participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica (LMC) en fase cr\u00f3nica reci\u00e9n diagnosticados \u00a0 Potencial del asciminib en el tratamiento de la LMC El objetivo del estudio es investigar la seguridad y eficacia [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7631,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,31],"tags":[],"class_list":["post-7558","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-estudio","category-noticias-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Asciminib en el tratamiento de la Leucemia Mieloide Cr\u00f3nica (LMC)<\/title>\n<meta name=\"description\" content=\"FTH CRO participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica en fase cr\u00f3nica reci\u00e9n diagnosticados\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fth.es\/pearl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asciminib en el tratamiento de la Leucemia Mieloide Cr\u00f3nica (LMC)\" \/>\n<meta property=\"og:description\" content=\"FTH CRO participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica en fase cr\u00f3nica reci\u00e9n diagnosticados\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fth.es\/pearl\/\" \/>\n<meta property=\"og:site_name\" content=\"Fundaci\u00f3n Te\u00f3filo Hernando\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-09T12:41:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-24T08:09:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fth.es\/wp-content\/uploads\/2025\/09\/examen-medico_16-9.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"665\" \/>\n\t<meta property=\"og:image:height\" content=\"375\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Elena Arias\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elena Arias\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/\"},\"author\":{\"name\":\"Elena Arias\",\"@id\":\"https:\\\/\\\/fth.es\\\/#\\\/schema\\\/person\\\/71d2bcaf0a418c5f6c25a3a2db51c4d1\"},\"headline\":\"Estudio cl\u00ednico PEARL (PotEntial of Asciminib in the eaRly treatment of CML)\",\"datePublished\":\"2025-09-09T12:41:16+00:00\",\"dateModified\":\"2025-09-24T08:09:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/\"},\"wordCount\":353,\"image\":{\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fth.es\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/examen-medico_16-9.jpeg\",\"articleSection\":[\"Estudio\",\"Noticias\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/\",\"url\":\"https:\\\/\\\/fth.es\\\/pearl\\\/\",\"name\":\"Asciminib en el tratamiento de la Leucemia Mieloide Cr\u00f3nica (LMC)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fth.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fth.es\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/examen-medico_16-9.jpeg\",\"datePublished\":\"2025-09-09T12:41:16+00:00\",\"dateModified\":\"2025-09-24T08:09:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/fth.es\\\/#\\\/schema\\\/person\\\/71d2bcaf0a418c5f6c25a3a2db51c4d1\"},\"description\":\"FTH CRO participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica en fase cr\u00f3nica reci\u00e9n diagnosticados\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fth.es\\\/pearl\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fth.es\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/examen-medico_16-9.jpeg\",\"contentUrl\":\"https:\\\/\\\/fth.es\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/examen-medico_16-9.jpeg\",\"width\":665,\"height\":375,\"caption\":\"Consulta de oncolog\u00eda\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fth.es\\\/pearl\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fth.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio cl\u00ednico PEARL (PotEntial of Asciminib in the eaRly treatment of CML)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fth.es\\\/#website\",\"url\":\"https:\\\/\\\/fth.es\\\/\",\"name\":\"Fundaci\u00f3n Te\u00f3filo Hernando\",\"description\":\"P\u00e1gina oficial de la Fundaci\u00f3n Te\u00f3filo Hernando - FTH\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fth.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fth.es\\\/#\\\/schema\\\/person\\\/71d2bcaf0a418c5f6c25a3a2db51c4d1\",\"name\":\"Elena Arias\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e8aabfb7dd9d3a97a1d3ab95d2f5a173b80c2318c9fa0a49c837c00a06022a57?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e8aabfb7dd9d3a97a1d3ab95d2f5a173b80c2318c9fa0a49c837c00a06022a57?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e8aabfb7dd9d3a97a1d3ab95d2f5a173b80c2318c9fa0a49c837c00a06022a57?s=96&d=mm&r=g\",\"caption\":\"Elena Arias\"},\"url\":\"https:\\\/\\\/fth.es\\\/en\\\/author\\\/elena-ariasifth-es\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Asciminib en el tratamiento de la Leucemia Mieloide Cr\u00f3nica (LMC)","description":"FTH CRO participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica en fase cr\u00f3nica reci\u00e9n diagnosticados","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fth.es\/pearl\/","og_locale":"en_US","og_type":"article","og_title":"Asciminib en el tratamiento de la Leucemia Mieloide Cr\u00f3nica (LMC)","og_description":"FTH CRO participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica en fase cr\u00f3nica reci\u00e9n diagnosticados","og_url":"https:\/\/fth.es\/pearl\/","og_site_name":"Fundaci\u00f3n Te\u00f3filo Hernando","article_published_time":"2025-09-09T12:41:16+00:00","article_modified_time":"2025-09-24T08:09:48+00:00","og_image":[{"width":665,"height":375,"url":"https:\/\/fth.es\/wp-content\/uploads\/2025\/09\/examen-medico_16-9.jpeg","type":"image\/jpeg"}],"author":"Elena Arias","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Elena Arias","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fth.es\/pearl\/#article","isPartOf":{"@id":"https:\/\/fth.es\/pearl\/"},"author":{"name":"Elena Arias","@id":"https:\/\/fth.es\/#\/schema\/person\/71d2bcaf0a418c5f6c25a3a2db51c4d1"},"headline":"Estudio cl\u00ednico PEARL (PotEntial of Asciminib in the eaRly treatment of CML)","datePublished":"2025-09-09T12:41:16+00:00","dateModified":"2025-09-24T08:09:48+00:00","mainEntityOfPage":{"@id":"https:\/\/fth.es\/pearl\/"},"wordCount":353,"image":{"@id":"https:\/\/fth.es\/pearl\/#primaryimage"},"thumbnailUrl":"https:\/\/fth.es\/wp-content\/uploads\/2025\/09\/examen-medico_16-9.jpeg","articleSection":["Estudio","Noticias"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fth.es\/pearl\/","url":"https:\/\/fth.es\/pearl\/","name":"Asciminib en el tratamiento de la Leucemia Mieloide Cr\u00f3nica (LMC)","isPartOf":{"@id":"https:\/\/fth.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fth.es\/pearl\/#primaryimage"},"image":{"@id":"https:\/\/fth.es\/pearl\/#primaryimage"},"thumbnailUrl":"https:\/\/fth.es\/wp-content\/uploads\/2025\/09\/examen-medico_16-9.jpeg","datePublished":"2025-09-09T12:41:16+00:00","dateModified":"2025-09-24T08:09:48+00:00","author":{"@id":"https:\/\/fth.es\/#\/schema\/person\/71d2bcaf0a418c5f6c25a3a2db51c4d1"},"description":"FTH CRO participa en un ensayo cl\u00ednico multic\u00e9ntrico dirigido a pacientes con leucemia mieloide cr\u00f3nica en fase cr\u00f3nica reci\u00e9n diagnosticados","breadcrumb":{"@id":"https:\/\/fth.es\/pearl\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fth.es\/pearl\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fth.es\/pearl\/#primaryimage","url":"https:\/\/fth.es\/wp-content\/uploads\/2025\/09\/examen-medico_16-9.jpeg","contentUrl":"https:\/\/fth.es\/wp-content\/uploads\/2025\/09\/examen-medico_16-9.jpeg","width":665,"height":375,"caption":"Consulta de oncolog\u00eda"},{"@type":"BreadcrumbList","@id":"https:\/\/fth.es\/pearl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fth.es\/en\/"},{"@type":"ListItem","position":2,"name":"Estudio cl\u00ednico PEARL (PotEntial of Asciminib in the eaRly treatment of CML)"}]},{"@type":"WebSite","@id":"https:\/\/fth.es\/#website","url":"https:\/\/fth.es\/","name":"Fundaci\u00f3n Te\u00f3filo Hernando","description":"P\u00e1gina oficial de la Fundaci\u00f3n Te\u00f3filo Hernando - FTH","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fth.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fth.es\/#\/schema\/person\/71d2bcaf0a418c5f6c25a3a2db51c4d1","name":"Elena Arias","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e8aabfb7dd9d3a97a1d3ab95d2f5a173b80c2318c9fa0a49c837c00a06022a57?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e8aabfb7dd9d3a97a1d3ab95d2f5a173b80c2318c9fa0a49c837c00a06022a57?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e8aabfb7dd9d3a97a1d3ab95d2f5a173b80c2318c9fa0a49c837c00a06022a57?s=96&d=mm&r=g","caption":"Elena Arias"},"url":"https:\/\/fth.es\/en\/author\/elena-ariasifth-es\/"}]}},"_links":{"self":[{"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/posts\/7558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/comments?post=7558"}],"version-history":[{"count":7,"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/posts\/7558\/revisions"}],"predecessor-version":[{"id":7624,"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/posts\/7558\/revisions\/7624"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/media\/7631"}],"wp:attachment":[{"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/media?parent=7558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/categories?post=7558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fth.es\/en\/wp-json\/wp\/v2\/tags?post=7558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}